Document Detail


The endothelin-converting enzyme-1/endothelin-1 pathway plays a critical role in inflammation-associated premature delivery in a mouse model.
MedLine Citation:
PMID:  18772340     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Premature delivery occurs in 12% of all births and accounts for nearly half of long-term morbidity. Current therapeutic approaches to preterm delivery are ineffective and present serious risks to both mother and fetus. The single most common cause of preterm birth is infection. Previous in vitro investigations have shown that endothelin-1 (ET-1) is induced by inflammatory cytokines and that it increases myometrial smooth muscle tone. Furthermore, we have previously shown that both the endothelin-converting enzyme-1 (ECE-1) inhibitor, phosphoramidon, as well as a novel ET-1 receptor A antagonist synthesized by our group, control premature delivery in a mouse model of inflammation-associated preterm delivery. In the current work, we show that levels of both ET-1 and ECE-1 are increased in gestational tissues in E16.5 mice induced to deliver prematurely after lipopolysaccharide administration. We also show that premature delivery is controlled by treatment with the selective endothelin receptor A antagonist BQ-123 in a dose-dependent manner. Finally, we show here for the first time that premature delivery can be controlled using RNA silencing, by hydrodynamic transfection of E15 mice with ECE-1 RNAi. Taken together, these data support a critical role for the ECE-1/ET-1 system in inflammation-associated premature delivery. The ability to control premature delivery by antagonizing or silencing the ECE-1/ET-1 system offers a novel approach to an unmet clinical need.
Authors:
Wei Wang; Haoting Yen; Hauting Yen; Chih-Hung Chen; Rimabahen Soni; Nitesh Jasani; Georges Sylvestre; Sandra E Reznik
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2008-09-04
Journal Detail:
Title:  The American journal of pathology     Volume:  173     ISSN:  1525-2191     ISO Abbreviation:  Am. J. Pathol.     Publication Date:  2008 Oct 
Date Detail:
Created Date:  2008-09-25     Completed Date:  2008-10-08     Revised Date:  2013-06-05    
Medline Journal Info:
Nlm Unique ID:  0370502     Medline TA:  Am J Pathol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1077-84     Citation Subset:  AIM; IM    
Affiliation:
Department of Pharmaceutical Sciences, St. John's University, Queens, NY 11439, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Aspartic Acid Endopeptidases / metabolism*
Endothelin-1 / metabolism*
Female
Immunohistochemistry
Inflammation / enzymology*
Lipopolysaccharides / pharmacology
Metalloendopeptidases / metabolism*
Mice
Mice, Inbred C57BL
Models, Animal*
Obstetric Labor, Premature / enzymology
Peptides, Cyclic / pharmacology
Placenta / cytology,  drug effects,  enzymology
Pregnancy
Premature Birth / enzymology*
RNA, Small Interfering / metabolism
Receptor, Endothelin A / antagonists & inhibitors
Uterus / cytology,  drug effects,  enzymology
Grant Support
ID/Acronym/Agency:
1K08HD01209/HD/NICHD NIH HHS
Chemical
Reg. No./Substance:
0/Endothelin-1; 0/Lipopolysaccharides; 0/Peptides, Cyclic; 0/RNA, Small Interfering; 0/Receptor, Endothelin A; 136553-81-6/cyclo(Trp-Asp-Pro-Val-Leu); EC 3.4.23.-/Aspartic Acid Endopeptidases; EC 3.4.24.-/Metalloendopeptidases; EC 3.4.24.71/endothelin-converting enzyme
Comments/Corrections
Erratum In:
Am J Pathol. 2009 Mar;174(3):1120.
Note: Yen, Hauting [corrected to Yen, Haoting]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Overexpression of NANOG in gestational trophoblastic diseases: effect on apoptosis, cell invasion, a...
Next Document:  Gene silencing of complement C5a receptor using siRNA for preventing ischemia/reperfusion injury.